339 THE ECONOMIC CONSEQUENCES OF KIDNEY, BLADDER, AND PROSTATE CANCER IN WASHINGTON STATE

Abstract

You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness I1 Apr 2010339 THE ECONOMIC CONSEQUENCES OF KIDNEY, BLADDER, AND PROSTATE CANCER IN WASHINGTON STATE Dan Lewinshtein, Paul Kozlowski, and Christopher Porter Dan LewinshteinDan Lewinshtein More articles by this author , Paul KozlowskiPaul Kozlowski More articles by this author , and Christopher PorterChristopher Porter More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.405AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We explored the financial cost of managing various urologic malignancies, and compared them to current expenditure on research. The adequate evaluation of the economic cost and length of hospital stay due to cancer burden was evaluated. METHODS We retrospectively reviewed the Comprehensive Hospital Abstract Reporting System (CHARS) from the Washington State Department of Health. We searched for all patients that had presented to a Washington State hospital and were either admitted to the ward, or seen in the emergency room (ER), with a primary diagnosis of kidney, bladder, or prostate cancer in both 2007 and 2008. Diagnoses and procedures were obtained from ICD9 codes. We quantified cost of stay and length of stay (LOS), and used the Kruskal-Wallis method to test for a difference between the median of each population. Total cost of care was then compared to published National Cancer Institute (NCI) values for urologic oncology funding. RESULTS There were 6908 visits to hospitals during the study period. Of those, 1736, 787, and 4385, were for kidney, bladder and prostate cancer, respectively. The median ages for patients with kidney, bladder, and prostate cancer were 61, 73, and 64 years respectively. The median LOS on the ward (5 days, p<0.001) and in the ER (78 hours, p<0.001) were longest for those with bladder cancer and kidney cancer, respectively. The median number of procedures performed per visit was highest for bladder cancer patients (n=3, p<0.001).The median charge per visit was highest for those with kidney cancer ($30,045, p<0.001). Total cumulative cost of care during the two year study period was highest for prostate cancer with a sum of $126,000,000. According to NCI cancer data, kidney, bladder and prostate cancer received $43,431,683, $24,053,694, and $285,400,863, respectively, in research funding in 2008, Thus kidney, bladder, and prostate received 0.69, 0.78, and 2.27 in research dollars per dollar of hospital cost. CONCLUSIONS Prostate cancer is a more common malignancy and accrued a higher toal cost. However, individual patient management for kidney cancer is highest among the three malignacies. Given the higher costs of bladder cancer and kidney cancer per individual, it could be argued that research funding for these malignancies should be brought up to the level of prostate cancer funding. Seattle, WA© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e135 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dan Lewinshtein More articles by this author Paul Kozlowski More articles by this author Christopher Porter More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...